Acute Hepatitis C Virus Infection Treated with Daclatasvir/Sofosbuvir in a 9-Year-Old Boy

The present study includes a case report of a 9-year-old boy who came to our center with jaundice, elevated liver enzymes, and palpable liver. He was treated with ursodeoxycholic acid, but no improvement in symptoms was seen. Reverse transcription polymerase chain reaction and liver biopsy were positive for hepatitis C virus. He was treated with daclatasvir/sofosbuvir for 3 months. Daclatasvir/sofosbuvir might be effective against the treatment of hepatitis in children, with no report of remission and minimal side effects.

[1]  P. Bradley,et al.  The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. , 2020, International journal of surgery.

[2]  R. Chung,et al.  Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. , 2018, Methods in molecular biology.

[3]  M. Moafy,et al.  Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4 , 2018, Journal of viral hepatitis.

[4]  M. El-Shabrawi,et al.  Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection , 2018, Journal of pediatric gastroenterology and nutrition.

[5]  Chen Li,et al.  A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection , 2018, Medicine.

[6]  L. Abu-Raddad,et al.  The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses , 2018, Scientific Reports.

[7]  O. Ogbuagu,et al.  Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection , 2018, Expert opinion on drug metabolism & toxicology.

[8]  S. Chow,et al.  Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection , 2017, Open forum infectious diseases.

[9]  M. El-Shabrawi,et al.  Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection , 2017, Journal of pediatric gastroenterology and nutrition.

[10]  J. Rockstroh,et al.  Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. , 2017, The lancet. Gastroenterology & hepatology.

[11]  W. Balistreri,et al.  Hepatitis C virus infection in children and adolescents , 2017, Hepatology communications.

[12]  S. Alavian,et al.  The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3 , 2016 .

[13]  T. Berg,et al.  Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort , 2016, Gut.

[14]  O. Weiland,et al.  Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations , 2015, Infectious diseases.

[15]  E. May,et al.  Profound jaundice in a patient with acute hepatitis C , 2013, BMJ Case Reports.